Enforcement Report - Week of June 26, 2024
Eugia Pharma Generic Busulfan Receives Approval in US
Eugia remains under FDA scrutiny as the unit of Indian drugmaker Aurobindo has received its fifth Form 483 since December.
FDA Issues Form 483 to Eugia Pharma Specialities
Enforcement Report - Week of April 17, 2024
The share price of Aurobindo Pharma fell in the early trade on April 8 after the company received three observations on its Andhra Pradesh subsidiary.
Eugia US LLC (f/k/a AuroMedics Pharma LLC) Issues Voluntary Nationwide Recall of Methocarbamol Injection Due to Presence of White Particles
Enforcement Report - Week of March 27, 2024
FDA Issues Form 483 to Eugia SEZ Private Limited